



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Working parties and new ways of working

11th Meeting of the Industry Stakeholder Platform on the operation of the centralised procedure for human medicines

Presented by Silvy da Rocha Dias on 24 November 2023
Head of Office Expert Panels and Groups

An agency of the European Union





Outline of presentation

- Working Party implementation project – update
- Stakeholder engagement – Workplans
- New EU survey tool to capture comments on guidelines



Timelines for the WP implementation plan






New model for the Working Parties

- **Domain** perform STORES (Strategic, Tactical, Operational, Reactive, Educational, Stakeholder) functions and produce three-year rolling strategic plans.
- Four organisational entities report to the domains governance:
 - **Working Parties** (WPs) have expertise in specific scientific fields and provide advice to the Committees
 - **Operational Expert Groups** (OEGs) => provide advice on specific scientific topics and support operational activities of the domain
 - **Temporary Drafting Groups** (tDGs) => responsible for drafting guidance documents.

Supported by:

- **European Specialised Expert Communities** (ESECs) => complement the knowledge within the domain by contributing to specific topics and are a source of expertise for the network.



Roadmap overview for the Quality Domain



- Initial 2-phase approach:
 - Phase 1: included Clinical, Non-clinical and Methodology domain;
 - Phase 2: Quality domain (QWP, BWP, BMWP, Paediatric Formulation-OEG, Herbal DG) following lessons learned exercise
- Balance for the memberships of the Biologics Working Party (BWP) and Quality Working Party (QWP), needed to consider:
 - The value of member state representation in an expertise-based model for BWP and QWP;
 - The need for alignment of approach across all working parties, with an “as needed” expertise composition which relies on active contribution of all expert members
- In March 2023, agreement at MB on an expertise-based model that provided flexibility on expertise and composition of WP



Phase 2 implementation of Quality domain: Main principles

- Established WPs in the Quality Domain function under main principles:
 - QWP and BWP WPs are established for a period of 3 years, BMWP membership follows a revision on annual basis
 - Quality domain prioritised expertise, taking into account the geographical spread of the nominations. Therefore, MS representation no longer key factor for membership
 - Continuously inactive members are to be replaced
 - EDQM maintains an observer status in BWP and QWP
 - ESEC establishment by nomination of Committee members, open call without set deadline, and may have the possibility to listen in BWP and QWP meetings

Stakeholder engagement

- Due to BCP and Covid-19, stakeholder engagement for WPs was paused temporarily
- Stakeholder Engagement at Domain level
 - Structured Stakeholder Engagement for priority planning and generation/revision of new/revised individual guidelines
 - Public/targeted consultation of workplans
- Stakeholder Engagement at WP level
 - Interested parties meetings:
 - general matters or specific scientific issues as foreseen in the 3-year rolling strategic plan
 - Webinars on new/revised guidelines with high public health impact
 - Workshops
 - Training



Workplans

- Pilot stakeholder consultation on 3-year rolling workplan for Methodology Domain
- Open consultation for 1 month
- Stakeholder interaction meeting to address comments on the workplan

Methodology Working Party stakeholder interaction meeting

[← Share](#)

Table of contents

- [Event summary](#)

Date: 07/12/2023

Location: Online

Event summary

Following the opening of the public consultation on the revised Methodology [Working Party](#) (MWP) workplan, a MWP stakeholder interaction meeting is taking place on 7 December 2023.

The main objectives of this meeting are to consolidate the comments received during the public consultation and to shape the updated MWP Workplan for the final endorsement for the [Committee for Medicinal Products for Human Use](#) (CHMP) preparatory and organisational matters (PROM) plenary meeting.

The meeting will be held virtually.

- [Register for this event](#)

Draft revised consolidated 3-year work plan for the Methodology Working Party (MWP) (PDF/246.96 KB)

Reference number EMA/CHMP/478317/2023

Status Draft: consultation open

First published 31/10/2023

Consultation dates 01/11/2023 to 30/11/2023

Summary The Methodology Working Party workplan constitutes the roadmap of MWP activities on the basis of evolving identified priorities. The updated workplan has been adopted by EMA's human medicines committee (CHMP) and is now open for public consultation.

All key stakeholders are therefore encouraged to provide their feedback through the [EU survey](#) by 30 November 2023.

If you respond on behalf of a company that is affiliated with an EU (trade) industry organisations, you are encouraged to share your comments to the respective affiliated EU (Trade) Industry organisation.



New EU survey tool to capture comments on guidelines

- Login is not required to fill in the survey
- Once submitted, comments can still be edited until the end of the consultation
- Can save the survey as draft
- Submitted comments sent to email as PDF copy
- Facilitates the collection of comments

0%

☒ Save a backup on your local computer (disable if you are using a public/shared computer)

Submission of comments on draft "Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders"

Fields marked with * are mandatory. [×](#)

Anonymous mode [×](#)
The anonymous option has been activated. As a result, your contribution to this survey will be anonymous as the system will not save any personal data such as your IP address.

Pages

- [Introduction to the survey](#)
- [Data Protection Statement and Consent](#)
- [Your details](#)
- [1. General comments](#)
- [2. Specific comments](#)
- [Executive summary](#)
- [2.1. Introduction \(background\)](#)
- [2.2. Scope](#)
- [2.3. Legal basis and relevant guidelines](#)
- [2.4. Patient selection](#)
- [2.4.2. Selection of seizure types and epilepsy syndromes](#)
- [2.5. Assessment of efficacy](#)
- [2.6. Study design](#)
- [2.7. Safety aspects](#)
- [2.8. Studies in special populations](#)
- [Other comments](#)
- [Other comments](#)
- [Submission of responses](#)

Introduction to the survey on draft Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders

Please click [here](#) to be redirected to the guideline text. The public consultation is launched on 10 November 2023 until 30 January 2024.

Views
[Standard](#) Accessibility Mode

Languages
English [▼](#)

Contact
[Contact Form](#)

[Save as Draft](#)

[Report abuse](#)



Summary

- Successful implementation of the re-organisation of the working parties from the Quality, Non-clinical, Methodology and Clinical domains
 - Quality domain prioritised expertise instead of MS representation, taking into account the geographical spread of the nominations
 - Review of the membership of WPs on an annual basis, BWP and QWP are established for a period of 3 years
- Stakeholder engagement with specific aims at the Domain and WP level
- Pilot on public consultation of 3-year rolling workplan for MWP
- New EU survey digital tool used for collection of comments rolled out for all public consultations of guidelines



Any questions?

Further information

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact

Follow us on  **@EMA_News**